Education:
1978-1983 B.S., Clinical Medicine Shanghai Medical College of Fudan University, Shanghai, China
1983-1986 Resident Physician, Department of Allergy, PUMC Hospital, Chinese Academy of Medical Sciences，Beijing, China
1986-1990 Ph.D., Medicine University of Miami, Florida, USA
Professional Positions:
1991-1993 Postdoc, National Jewish Center for Immunology and Respiratory Medicine, USA
1994-1998 Senior Specialist Resident, University of Washington, USA
1998-2005 Associate professor, The University of Chicago, USA
2005-2015 Professor (tenured), The University of Chicago, USA
2015-2021 Professor, University of Texas, Southwestern Medical Center at Dallas, UTSW, USA
2021-Now Tsinghua University School of Basic Medical Sciences, Director and Chair
Professor, Center for Cancer Biology, Beijing, China
Research Areas:
My research areas are immunotherapy and immunopathology for cancer and infectious diseases. We have researched and developed new strategies for the cellular and molecular mechanisms of tumor immunity and targeted therapy for tumors, which better combine enhanced conventional therapy with immunotherapy. The combination of the two can more effectively kill tumor cells, while optimally mobilizing host immunity to achieve complete tumor regression and prevention of metastasis. Our laboratory has developed novel immunotherapy molecules, antibodies, and armed antibodies through protein engineers to overcome these resistance mechanisms and improve and sustainably control tumors. We will continue to develop next-generation antibodies or cytokines for cancer immunotherapy. My major contribution to science is to be the first to propose the theory of tumor radiotherapy induced immune response, revealing the intracellular STING signaling and the interaction mechanism between immune cells; Pioneering cytokine prodrug design for the treatment of various solid tumors. Up to date, I have published over 260 research papers in top academic journals such as Science, Nature, and Nature Medicine, with more than 50000 citations and an H-index of 115. From 2019 to 2023, I was selected as a "Highly Cited Scientist" by Clarivate, becoming one of the few doctors and scientists who have achieved outstanding results in both medicine and basic research fields.
Honors and Awards:
➢ 2015 Senior Investigator Award in CPRIT2022 MOE Changjiang Distinguished Professor
➢ 2015 Endowed Professor in U of Chicago and UTSW
➢ 2005 Guest Professor and adviser in Chinese Academy of Sciences
➢ 1999 NMSS Awardee
➢ 1997 Clinical Investigator Award (K08), NIAID
➢ 1997 Young Investigator Award, ACLPS
➢ 1996 Young Investigator Award, ACLPS
➢ 1991 Howard Hughes Medical Institute Fellowship for Physician Scientists
Selected Publications:
1.Tumbath S, Jiang L, Li X, Zhang T, Zahid KR, Zhao Y, Zhou H, Yin Z, Lu T, Jiang S, Chen Y, Chen X, Fu YX*, Huang X. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers. Oncoimmunology. 2024 Jun 4;13(1):2363000.
2.Zou Z, Shen J, Xue D, Li H, Xu L, Cao W, Wang W, Fu YX*, Peng H. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses. Nat Commun. 2024 Jun 3;15(1):4701.
3.Bugno J, Wang L, Yu X, Cao X, Wang J, Huang X, Yang K, Piffko A, Chen K, Luo SY, Naccasha E, Hou Y, Fu S, He C, Fu YX, Liang HL, Weichselbaum RR. Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance. Clin Cancer Res. 2024
4.Wang W, Fu YX*. Promises and challenges of organoids: From humanized to human derived.Cell Stem Cell. 2024 Mar 7;31(3):281-282.
5.Huang J, Zhang X, Xu H, Fu L, Liu Y, Zhao J, Huang J, Song Z, Zhu M, Fu YX, Chen YG, Guo X. Intraepithelial Lymphocytes Promote Intestinal Regeneration through CD160/HVEM Signaling. Mucosal Immunol. 2024 Feb 8:S1933-0219(24)00008-4.
6.Liu G, Ma N, Cheng K, Feng Q, Ma X, Yue Y, Li Y, Zhang T, Gao X, Liang J, Zhang L, Wang X, Ren Z, Fu YX, Zhao X, Nie G. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. Nat Nanotechnol. 2023 Dec 5
7.Wang J, Li S, Wang M, Wang X, Chen S, Sun Z, Ren X, Huang G, Sumer BD, Yan N, Fu YX, Gao J. STING licensing of type I dendritic cells potentiates antitumor immunity. Sci Immunol. 2024 Feb 16;9(92):eadj3945.
8.Huang Y, Lu C, Wang H, Gu L, Fu YX*, Li GM. DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability. Nat Commun. 2023 Aug 28;14(1):5246
9.Facts and hopes on chimeric cytokine agents for cancer immunotherapy. Ren Z, Zhang X, Fu YX. Clin Cancer Res. 2024 Jan 8. doi: 10.1158/1078-0432.
10.Huang Y, Lu C, Wang H, Gu L, Fu YX*, Li GM. DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability. Nat Commun. 2023 Aug 28;14(1):5246.
11.Wang X, Liu L, Yue T, Sun Z, Bae J, Tseng KF, Zhang A, Qiao J, Fu YX*. Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells. Signal Transduct Target Ther. 2023 Jul 12;8(1):268.
12.Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, Wang B, Schones DE, Fu YX*, Riggs AD, Martin PJ, Feng R, Zeng D. Share. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci U S A. 2023， 120(16):e2205085120
13.Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, Wang B, Schones DE, Fu YX*, Riggs AD, Martin PJ, Feng R, Zeng D. Share. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci U S A. 2023， 120(16):e2205085120
14.He Q, Sun S, Chen X, Hu Z, Zhang Y, Peng H, Fu YX*, Yang J, Chen L. The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages J Clin Med. 2022 Dec 24;12(1):146
15.Peng H, Fu YX*. Towards developing a variant-proof SARS-CoV-2 vaccine. Cell Res. 2023. 33(1):5-6
16.Meng CY, Sun S, Liang Y, Xu H, Zhang C, Zhang M, Wang FS, Fu YX*, Peng H. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut. 2023. 72(8):1544-1554，
17.Bae J, Liu L, Moore C, Hsu E, Zhang A, Ren Z, Sun Z, Wang X, Zhu J, Shen J, Qiao J, Fu YX*. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer. Nat Cell Biol. 2022 24(12):1754-1765.
18.He Q, Sun S, Chen X, Hu Z, Zhang Y, Peng H, Fu YX, Yang J, Chen L. The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages. J Clin Med. 2022 Dec 24;12(1):146.
19.Shen J, Zou Z, Guo J, Cai Y, Xue D, Liang Y, Wang W, Peng H, Fu YX*. An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. J Exp Med. 2022 Dec 5;219(12): e20220745.
20.Yang K, Han W, Jiang X, Piffko A, Bugno J, Han C, Li S, Liang H, Xu Z, Zheng W, Wang L, Wang J, Huang X, Ting JPY, Fu YX, Lin W, Weichselbaum RR. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat Nanotechnol. 2022 Dec;17(12):1322-1331.
21.Moore C, Bae J, Liu L, Li H, Fu YX*, Qiao J. Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. JCI Insight. 2022 Sep 8;7(17):e159479
22.Feng Q, Liu Z, Yu X, Huang T, Chen J, Wang J, Wilhelm J, Li S, Song J, Li W, Sun Z, Sumer BD, Li B, Fu YX*, Gao J. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat Commun. 2022 Sep 6;13(1):4981.
23.Zhang Z, He Q, Zhao W, Li Y, Yang J, Hu Z, Chen X, Peng H, Fu YX, Chen L, Lu L. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. J Clin Med. 2022 Jul 18;11(14):4164.
24.Li F, Zhang H, Wang W, Yang P, Huang Y, Zhang J, Yan Y, Wang Y, Ding X, Liang J, Qi X, Li M, Han P, Zhang X, Wang X, Cao J, Fu YX*, Yang X. T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies. Nat Commun. 2022 Jul 26;13(1):4334.
25.Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, González Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX*, Hanker AB, Arteaga CL. Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer Immunol Res. 2022 Jul 1;10(7):829-843
26.Lin Y, Sun J, Cao X, Wang X, Chen X, Xu H, Zhao J, Fu YX*, Peng H. Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2. Cell Discov. 2022 May 10;8(1):43.
27.Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1 + CD8 T cells. Cell Rep Med. 2022 Mar 15;3(3):100554.
28.Liu L, Chen J, Zhang H, Ye J, Moore C, Lu C, Fang Y, Fu YX*, Li B. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nat Cancer. 2022 Apr;3(4):437-452
29.Peng H, Fu YX*. Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine. Cell Res. 2022 Apr;32(4):331-332.
30.Ren Z, Zhang A, Sun Z, Liang Y, Ye J, Qiao J, Li B, Fu YX*. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity。J Clin Invest。 2022 Feb 1;132(3):e153604.
31.Xue D, Moon B, Liao J, Guo J, Zou Z, Han Y, Cao S, Wang Y, Fu YX*, Peng H. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors。Sci Immunol 2022 Jan 7;7(67):eabi6899
32.Song S, Zhou B, Cheng L, Liu W, Fan Q, Ge X, Peng H, Fu YX, Ju B, Zhang Z. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice. Virol J. 2022 Jan 4;19(1):2.
33.Sun S, Chen X, Lin J, Ai J, Yang J, Hu Z, Fu YX*, Peng H. Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01. Cell Discov. 2021.7(1):114.
34.Liu L, Chen J, Bae J, Li H, Sun Z, Moore C, Hsu E, Han C, Qiao J, Fu YX*. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nat Biomed Eng. 2021 5(11):1261-1273.
35.Rao E, Hou Y, Huang X, Wang L, Wang J, Zheng W, Yang H, Yu X, Yang K, Bugno J, Ding X, Vokes E, Fu YX*. Weichselbaum RR, Liang HL All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021 Jun 15;6(60):eaba8426.
36.Cao X, Liang Y, Hu Z, Li H, Yang J, Hsu EJ, Zhu J, Zhou J, Fu YX*. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat Commun. 2021 Oct 7;12(1):5866.
37.Hannan R, Mohamad O, Diaz de Leon A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga Y, Courtney K, Cantarel B, Wakeland EK, Fu YX, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021 Sep 22:clincanres.2083.2021.
38.Guo J, Liang Y, Xue D, Shen J, Cai Y, Zhu J, Fu YX*, Peng H. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021 Aug 10. doi: 10.1038/s41422-021-00543-4.
39.Zhang A, Ren Z, Tseng KF, Liu X, Li H, Lu C, Cai Y, Minna JD, Fu YX*. Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Sci Transl Med. 2021 Aug 4;13(605):eabg8693.
40.Rodriguez AB, Peske JD, Woods AN, Leick KM, Mauldin IS, Meneveau MO, Young SJ, Lindsay RS, Melssen MM, Cyranowski S, Parriott G, Conaway MR, Fu YX, Slingluff CL Jr, Engelhard VH. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 2021 Jul 20;36(3):109422
41.Sun S, Cai Y, Song TZ, Pu Y, Cheng L, Xu H, Sun J, Meng C, Lin Y, Huang H, Zhao F, Zhang S, Gao Y, Han JB, Feng XL, Yu DD, Zhu Y, Gao P, Tang H, Zhao J, Zhang Z, Yang J, Hu Z, Fu YX, Zheng YT, Peng H. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021 Sep;31(9):1011-1023.
42.Hsu EJ, Cao X, Moon B, Bae J, Sun Z, Liu Z, Fu YX*. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat Commun. 2021, 12(1):2768.
43.Han C, Godfrey V, Liu Z, Han Y, Liu L, Peng H, Weichselbaum RR, Zaki H, Fu YX*. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Sci Immunol. 2021, 6(59):eabc6998.
44.Moore C, Hsu CC, Chen WM, Chen BPC, Han C, Story M, Aguilera T, Pop LM, Hannan R, Fu YX, Saha D, Timmerman R Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys. 2021 Mar 29:S0360-3016(21)00309-6.
45.He Y, Fu L, Li Y, Wang W, Gong M, Zhang J, Dong X, Huang J, Wang Q, Mackay CR, Fu YX, Chen Y, Guo X. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metab. 2021 33(5):988-1000.e7.
46.Liang Y, Hannan R, Fu YX*. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. Clin Cancer Res. 2021, doi: 10.1158/1078-0432
47.Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu YX, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-X L destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021, 12(1):1281.
48.Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, Huang X, Wang L, Li L, Bugno J, Fu Y, Chmura SJ, Wu W, Luo SZ, Zheng W, Arina A, Jutzy J, McCall AR, Vokes EE, Pitroda SP, Fu YX*, Weichselbaum RR. Sci Transl Med. 2021,13(578):eaba7308.
49.Li S, Luo M, Wang Z, Feng Q, Wilhelm J, Wang X, Li W, Wang J, Cholka A, Fu YX, Sumer BD, Yu H, Gao J. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat Biomed Eng. 2021, 5(5):455-466.
50.Zhang H, Li F, Cao J, Wang X, Cheng H, Qi K, Wang G, Xu K, Zheng J, Fu YX*, Yang X. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Sci Transl Med. 2021 13(578):eaba7308.
51.Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX*, Weichselbaum RR. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 Mar 1;218(3):e20201915.
52.Son YM, Cheon IS, Wu Y, Li C, Wang Z, Gao X, Chen Y, Takahashi Y, Fu YX, Dent AL, Kaplan MH, Taylor JJ, Cui W, Sun J. Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses. Sci Immunol. 2021 Jan 8;6(55):eabb6852.
53.Guan J, Lu C, Jin Q, Lu H, Chen X, Tian L, Zhang Y, Ortega J, Zhang J, Siteni S, Chen M, Gu L, Shay JW, Davis AJ, Chen ZJ, Fu YX*, Li GM. MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. Cancer Cell. 2020 39(1):109-121
54.Lu C, Guan J, Lu S, Jin Q, Rousseau B, Lu T, Stephens D, Zhang H, Zhu J, Yang M, Ren Z, Liang Y, Liu Z, Han C, Liu L, Cao X, Zhang A, Qiao J, Batten K, Chen M, Castrillon DH, Wang T, Li B, Diaz LA Jr, Li GM, Fu YX*. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell. 2020 39(1):96-108.
55.Han C, Zhang A, Liu Z, Moore C, Fu YX*. Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy. Oncogene. 2020 40(5):885-898
56.Wang Y, Luo M, Chen Y, Wang Y, Zhang B, Ren Z, Bao L, Wang Y, Wang JE, Fu YX, Luo W, Wang Y. ZMYND8 expression in breast cancer cells blocks T-lymphocyte surveillance to promote tumor growth. Wang Y, Luo M, Chen Y, Wang Y, Zhang B, Ren Z, Bao L, Wang Y, Wang JE, Fu YX, Luo W, Wang Y. Cancer Res. 1710.2020.
57.Zheng W, Ranoa DRE, Huang X, Hou Y, Yang K, Poli EC, Beckett MA, Fu YX*, Weichselbaum RR. RIG-I-like receptor LGP2 is required for tumor control by radiation therapy. Cancer Res. 2020 Oct 21:canres.2324.2020.
58.Zhang L, Zhang A, Xu J, Qiu C, Zhu L, Qiu C, Fu W, Wang Y, Ye L, Fu YX, Zhao C, Zhang X, Xu J. CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells. Front Immunol. 11:2188; 2020.
59.Rao L, Wu L, Liu Z, Tian R, Yu G, Zhou Z, Yang K, Xiong HG, Zhang A, Yu GT, Sun W, Xu H, Guo J, Li A, Chen H, Sun ZJ, Fu YX, Chen X. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis Nat Commun. 2020 Sep 30;11(1):4909.
60.Suresh S, Chen B, Zhu J, Golden RJ, Lu C, Evers BM, Novaresi N, Smith B, Zhan X, Schmid V, Jun S, Karacz CM, Peyton M, Zhong L, Wen Z, Sathe AA, Xing C, Behrens C, Wistuba II, Xiao G, Xie Y, Fu YX, Minna JD, Mendell JT, O'Donnell KA. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat Cancer. 2020 1(5):533-545.
61.Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, Guo J, Peng H, Chen M, Fu YX*, Tang H. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020 Sep 24;11(1):4835
62.Han C, Fu YX*. β-Catenin regulates tumor-derived PD-L1. J Exp Med 2020 Nov 2;217(11):e20200684
63.Beshnova D, Ye J, Onabolu O, Moon B, Zheng W, Fu YX, Brugarolas J, Lea J, Li B. De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. Sci Transl Med 12(557):eaaz3738, 2020
64.Peng H, Fu YX*. The Inhibitory PVRL1/PVR/TIGIT Axis in Immune Therapy for Hepatocellular Carcinoma. Gastroenterology S0016-5085(20)34822-8, 2020
65.Wang W, Li Y, Hao J, He Y, Dong X, Fu YX*, Guo X*. The Interaction between Lymphoid Tissue Inducer-Like Cells and T Cells in the Mesenteric Lymph Node Restrains Intestinal Humoral Immunity, Cell report 32(3):107936. 2020
66.Mender I, Zhang A, Ren Z, Han C, Deng Y, Siteni S, Li H, Zhu J, Vemula A, Shay JW, Fu YX*. Telomere Stress Potentiates Host STINT Dependent Anti-Tumor Immunity Cancer Cell S1535-6108(20)30270-1. 2020
67.Li HD, Lu C, Zhang H, Hu Q, Zhang J, Cuevas IC, Sahoo SS, Aguilar M, Maurais EG, Zhang S, Wang X, Akbay EA, Li GM, Li B, Koduru P, Ly P, Fu YX*, Castrillon DH. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight 2020 Jul 23;5(14):138829.
68.Zuo H, Yang D, Yang Q, Tang H, Fu YX*, Wan Y. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nat Commun. 2020 Mar 27;11(1):1578. PMC7101362
69.Deng S, Sun Z, Qiao J, Liang Y, Liu L, Dong C, Shen A, Wang Y, Tang H, Fu YX*, Peng H. Targeting Tumors With IL-21 Reshapes the Tumor Microenvironment by Proliferating PD-1intTim-3-CD8+ T Cells JCI Insight. 2020 Apr 9;5(7):e132000.
70.Zhang H, Liu L, Zhang J, Chen J, Ye J, Shukla S, Qiao J, Zhan X, Chen H, Wu CJ, Fu YX*, Li B. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. Clin Cancer Res. 2020 26(6):1359-1371.
71.Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, Wang Z, Zhu P, Peng H, Yan X, Li W, Fu YX*, Zhu M. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat Nanotechnol. 2020.
72.Shi Y, Zheng W, Yang K, Harris KG, Ni K, Xue L, Lin W, Chang EB, Weichselbaum RR, Fu YX*. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020 217(5):e20192282.
73.Liu Z, Fu YX. Chemotherapy Induces Cancer-Fighting B Cells. Cell. 2020 Mar 19;180(6):1037-1039.
74.Zuo H, Yang D, Yang Q, Tang H, Fu YX*, Wan Y. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nat Commun. 2020 11(1):1578.
75.Han C, Liu Z, Zhang Y, Shen A, Dong C, Zhang A, Moore C, Ren Z, Lu C, Cao X, Zhang CL, Qiao J, Fu YX*. Tumor Cells Suppress Radiation-Induced Immunity by Hijacking Caspase 9 Signaling. Nat Immunol. 2020, .21(5):546-554.
76.Deng S, Sun Z, Qiao J, Liang Y, Liu L, Dong C, Shen A, Wang Y, Tang H, Fu YX*, Peng H*. Targeting Tumors With IL-21 Reshapes the Tumor Microenvironment by Proliferating PD-1intTim-3-CD8+ T Cells. JCI Insight. 2020 Apr 9;5(7):132000.
Complete list of publications:
All publications in Chinese Medical Journals are not included
http://www.ncbi.nlm.nih.gov/pubmed/?term=yang-xin+fu
https://scholar.google.com/citations?user=UU4QhnoAAAAJ&hl=en
